Aduro BioTech, Inc.
(NASDAQ : ADRO)

( )
ADRO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.27%93.671.3%$1008.13m
BIIBBiogen Inc.
0.61%230.211.3%$687.10m
AMGNAmgen Inc.
1.93%179.761.3%$470.05m
GILDGilead Sciences, Inc.
1.89%63.040.9%$441.53m
ILMNIllumina, Inc.
0.93%322.063.5%$285.16m
REGNRegeneron Pharmaceuticals, Inc.
3.03%344.142.6%$275.35m
VRTXVertex Pharmaceuticals Incorporated
4.07%175.371.9%$247.10m
ALXNAlexion Pharmaceuticals, Inc.
2.64%132.372.0%$175.19m
EXASExact Sciences Corporation
3.61%93.9425.3%$160.74m
SRPTSarepta Therapeutics, Inc.
3.78%118.0914.7%$144.55m
AAgilent Technologies, Inc.
-0.04%75.541.6%$142.04m
ONCESpark Therapeutics, Inc.
0.00%110.6011.2%$133.55m
INCYIncyte Corporation
2.38%75.412.5%$98.69m
IONSIonis Pharmaceuticals, Inc.
3.25%75.008.3%$95.31m
BMRNBioMarin Pharmaceutical Inc.
2.74%86.004.3%$93.68m

Company Profile

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.